-
Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology
In the era of medical innovation, various targeted and immune drugs are emerging, leading to breakthroughs in lymphoma treatment. From January 26th to 28th, 2024, the “Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, as well as the 2024 CSCO Hematology and Lymphoma, and Myeloma…
-
Professor Hui Wei: Mutual learning and progress, new treatment strategies and future directions in the field of leukemia | 2024 CSCO
With the rapid development of targeted therapy and immunotherapy, the field of leukemia treatment has undergone revolutionary changes. At the recently held “Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference,” domestic and international experts,…
-
ASCO-GU Interview | Dr. Tao Xu: Current status of precision treatment of prostate cancer and application of genetic testing
Oncology Frontier : With the ongoing of molecular research, the treatment of tumors has entered the era of precision medicine. At this ASCO-GU conference, we observed the release of data…
-
Professor DeHui Zou : Progress and Considerations in CAR-T Therapy for Diffuse Large B-Cell Lymphoma | 2024 CSCO Hematology Academic Conference
With unceasing exploration, the grand event took place as scheduled. From January 26 to 28, 2024, the “Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Committee Work Meeting and the 2024 CSCO Academic Conference on Hematology, Lymphoma, and Myeloma” was grandly held in the beautiful city of Haikou. Renowned experts and…
-
ASCO-GU Interview | Dr. Pengfei Shen Interprets PROpel Study, Shares Genetic Testing to Guide Precise Treatment of Prostate Cancer
Oncology Frontier : This ASCO-GU Symposium published several latest researches related to PARP inhibitors. Among them, the PROpel study revealed the efficacy of olaparib in combination with abiraterone compared to…
-
2024 CASH丨Professor Jinghui Zhang：Monitoring clonal hematopoiesis in pediatric patients helps improve long-term prognosis
Clonal hematopoiesis typically refers to the proliferation of hematopoietic stem cells due to genetic mutations, which is also the basis for various hematologic diseases; monitoring clonal hematopoiesis helps in early detection of hematologic malignancies. At the Fourth China Hematology Development Conference (CASH) held recently, Professor Jinghui Zhang from St. Jude Children’s Research Hospital shared a…
-
2024 CASH | Professor Ying Wang : Immunotherapy Brings Strong Vitality to the Treatment of Adult R/R ALL
The Fourth China Hematology Development Conference was held in Tianjin from January 5 to 7, 2024. Themed “Broad Hematology, Public Health, and Overall Well-being,” the conference centered around the core development directions of hematology, as well as major disciplinary issues faced in basic hematology research, translation, and clinical diagnosis and treatment in the new era.…
-
ASCO-GU Interview | Dr. Fufu Zheng Shares Advances in First-Line PARPi Treatment and Genetic Testing for mCRPC
Oncology Frontier: Numerous studies targeting the HRR pathway in prostate cancer emerged at this conference. For instance, the PROpel study on olaparib combined with NHA revealed data for the HRRm…
Connecting Medical Expertise through Media